Moleculin completes dosing in Phase 2/3 MIRACLE trial evaluating Annamycin. The company is on track to report comprehensive Part A data in Q1 2027, which is expected to support dose selection for Part B.
Moleculin completes dosing in Phase 2/3 MIRACLE trial evaluating Annamycin. The company is on track to report comprehensive Part A data in Q1 2027, which is expected to support dose selection for Part B.